This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Recalcitrant facial erythema often occurs in adults with atopic dermatitis and resists common therapies, including topical corticosteroids.¹ Recently, several authors have reported that short-term use of tacrolimus (FK506) ointment, a newly developed immunosuppressant drug, shows excellent results with recalcitrant facial erythema.^2-5 In the present study, we analyzed the effects of long-term applications of topical tacrolimus on red face conditions.

Patients and Methods

After obtaining informed consent, 51 adult patients (age range,16-44 years) with atopic dermatitis, who had steroid-resistant diffuse indurated erythema on the face for 1 to 23 years (average, 5 years), were included in the study. All fulfilled Hanifin and Rajka's diagnostic criteria⁶ for atopic dermatitis. Active skin lesions on the trunk and limbs were present on less than 10% of the total body surface in 27 patients, 10% to 50% of the body surface in 10 patients, and more than 50% of the body surface in 14 patients.

We prepared a . . . [Full Text of this Article]

Results

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical Tacrolimus
Rapaport
Arch Dermatol 2005;141:1468-1468.
FULL TEXT